Secukinumab (AIN457) showed superiority over Enbrel® in clearing skin, according to pivotal Novartis Phase III psoriasis results at EADV Novartis, 3 Oct 2013 Accessed on 28 Oct 2013 from http://www.novartis.com/newsroom/media-releases/en/2013/1733280.shtml. CommentRecommendBookmarkWatch
